Abstract
Dystonia is a syndrome of sustained involuntary muscle contractions, frequently causing twisting and repetitive movements or abnormal posturing. Cervical dystonia (CD) is a form of dystonia that involves neck muscles. However, CD is not the only cause of neck rotation. Torticollis may be caused by orthopaedic, musculofibrotic, infectious and other neurological conditions that affect the anatomy of the neck, and structural causes.
It is estimated that there are between 60 000 and 90 000 patients with CD in the US. The majority of the patients present with a combination of neck rotation (rotatory torticollis or rotatocollis), flexion (anterocollis), extension (retrocollis), head tilt (laterocollis) or a lateral or sagittal shift. Neck posturing may be either tonic, clonic or tremulous, and may result in permanent and fixed contractures.
Sensory tricks (‘geste antagonistique’) often temporarily ameliorate dystonic movements and postures. Commonly used sensory tricks by patients with CD include touching the chin, back of the head or top of the head.
Patients with CD are classified according to aetiology into two groups: primary CD (idiopathic — may be genetic or sporadic) or secondary CD (symptomatic). Patients with primary CD have no evidence by history, physical examination or laboratory studies (except primary dystonia gene) of any secondary cause for the dystonic symptoms. CD is a part of either generalised or focal dystonic syndrome which may have a genetic basis, with an identifiable genetic association. Secondary or symptomatic CD may be caused by central or peripheral trauma, exposure to dopamine receptor antagonists (tardive), neurodegenerative disease, and other conditions associated with abnormal functioning of the basal ganglia. In the majority of patients with CD, the aetiology is not identifiable and the disorder is often classified as primary.
Unless the aetiological investigation reveals a specific therapeutic intervention, therapy for CD is symptomatic. It includes supportive therapy and counselling, physical therapy, pharmacotherapy, chemodenervation [botulinum toxin (BTX), phenol, alcohol], and central and peripheral surgical therapy. The most widely used and accepted therapy for CD is local intramuscular injections of BTX-type A. Currently, both BTX type A and type B are commercially available, and type F has undergone testing. Pharmacotherapy, including anticholinergics, dopaminergic depleting and blocking agents, and other muscle relaxants can be used alone or in combination with other therapeutic interventions. Surgery is usually reserved for patients with CD in whom other forms of treatment have failed.
Similar content being viewed by others
Notes
Use of a tradename is for identification purposes only and does not imply endorsement.
Use of a tradename is for identification purposes only and does not imply endorsement.
Use of a tradename is for identification purposes only and does not imply endorsement.
Use of a tradename is for identification purposes only and does not imply endorsement.
References
Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworths, 1987: 332–58
Fahn S. The varied clinical expressions of dystonia. Neurol Clin 1984; 2(3): 541–54
Claypool DW, Duane DD, Ilstrup DM, et al. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord 1995; 10: 608–14
Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3: 188–94
Duffey PO, Butler AG, Hawthorne MR, et al. The epidemiology of the primary dystonias in the north of England. Adv Neurol 1998; 78: 121–5
Chan J, Brin M, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991; 6: 119–26
Jankovic J, Leder S, Warner D, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41: 1088–91
Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis — review of 220 patients. Can J Neurol Sci 1991; 18: 143–51
Duane DD. Spasmodic torticollis. Adv Neurol 1988;49: 135–50
Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group. Sex-related influences on the frequency and age of onset of primary dystonia. Neurology 1999; 53: 1871–3
Marsden CD. Investigation of dystonia. Adv Neurol 1988; 50: 35–44
Consky ES, Lang AE. Clinical assessments of patients with cervical Dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 211–37
Jorgenson C, Porphyris H. Idiopathic spasmodic torticollis. J Neurosurg Nurs 1985; 17: 169–74
Friedman A, Fahn S. Spontaneous remissions in spasmodic torticollis. Neurology 1986; 36: 398–400
Jahanshahi M, Marion MH, Marsden CD. Natural history of adult-onset idiopathic torticollis. Arch Neurol 1990; 47: 548–52
Jahanshahi M. Factors that ameliorate or aggravate spasmodic torticollis. J Neurol Neurosurg Psychiatry 2000; 68: 227–9
Wissel J, Müller J, Ebersbach G, et al. Trick maneuvers in cervical dystonia: investigation of movement- and touch-related changes in polymyographic activity. Mov Disord 1999; 14: 994–9
Greene PE, Bressman S. Exteroceptive and interoceptive stimuli in dystonia. Mov Disord 1998; 13: 549–5
Kutvonen O, Dastidar P, Nurmikko T. Pain in spasmodic torticollis. Pain 1997; 69(3): 279–86
Lowenstein DH, Aminoff MJ. The clinical course of spasmodic torticollis. Neurology 1988; 38: 530–2
Bressman SB, Sabatti C, Raymond D, et al. The dystonial phe-notype and guidelines for diagnostic testing [see comments]. Neurology 2000; 54: 1746–52
Brin MF. Dystonia: genetics and treatment with botulinum toxin. In: Smith B, Adelman G, editors. Neuroscience year: encyclopedia of neuroscience. Suppl. 2. Boston: Birkhauser, 1997: 56–8
Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP binding protein. Natl Gen 1997; 17: 40–8
Ozelius L, Kramer PL, Moskowitz CB, et al. Human gene for torsion dystonia located on chromosome 9q32-q 34. Neuron 1989; 2: 1427–34
Gimenez-Roldan S, Lopez-Fraile IP, Esteban A. Dystonia in Spain: study of a Gypsy family and general survey. Adv Neurol 1976; 14: 125–36
Haberhausen G, Schmitt I, Köhler A, et al. Assignment of the dystonia-parkinsonism syndrome locus, dystonia3, to a small region within a 1.8-Mb YAC contig of Xql3. 1. Am J Hum Genet 1995; 57: 644–50
Graeber MB, Kupke KG, Muller U. Delineation of the dystonia-parkinsonism syndrome locus in Xq l 3. Proc Natl Acad Sci U S A 1992; 89: 8245–8
Takahashi H, Snow B, Waters C, et al. Evidence for nigrostriatal lesions in Lubag (X-linked dystonia-parkinsonism in the Philippines). Neurology 1992; 42 Suppl. 3: 441
Lee LV, Kupke KG, Caballar Gonzaga F, et al. The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines. Medicine (Balt) 1991; 70: 179–87
Wilhelmsen KC, Weeks DE, Nygaard TG, et al. Genetic mapping of the ‘Lubag’ (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol 1991; 29: 124–31
Kupke KG, Lee LV, Muller U. Assignment of the X-linked torsion dystonia gene to Xq21 by linkage analysis. Neurology 1990; 40: 1438–42
Kupke KG, Lee LV, Viterbo GH, et al. X-linked recessive torsion dystonia in the Philippines. Am J Med Genet 1990; 36: 237–42
Kandil MR, Tohamy SA, Fattah MA, et al. Prevalence of chorea, dystonia and athetosis in Assiut, Egypt: a clinical and epidemiological study. Neuroepidemiology 1994; 13: 202–10
Parker N. Hereditary whispering dysphonia. J Neurol Neurosurg Psychiatry 1985; 48: 218–24
Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8: 236–42
Ichinose H, Ohye T, Matsuda Y, et al. Characterization of mouse and human GTP cyclohydrolase I genes. Mutations in patients with GTP cyclohydrolase I deficiency. J Biol Chem 1995; 270: 10062–71
Nygaard TG, Wilhelmsen KC, Risch NJ, et al. Linkage mapping of DOPA-responsive dystonia (Drd) to chromosome 14Q. Nat Genet 1993; 5: 386–91
Knappskog PM, Flatmark T, Mallet J, et al. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 1995; 4: 1209–12
Almasy L, Bressman SB, Raymond D, et al. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol 1997; 42: 670–3
Leube B, Rudnicki D, Ratzlaff T, et al. Idiopathic torsion dystonia: assignment of a gene to chromosome 18p in a german family with adult onset, autosomal dominant inheritance and purely focal distribution. Hum Mol Genet 1996; 5: 1673–7
Leube B, Hendgen T, Kessler KR, et al. Sporadic focal dystonia in northwest Germany: molecular basis on chromosome 18p. Ann Neurol 1997; 42(1): 111–4
Leube B, Hendgen T, Kessler KR, et al. Evidence for dystonia7 being a common cause of cervical dystonia (torticollis) in Central Europe. Am J Med Genet 1997; 74(5): 529–2
Raskind WH, Bolin T, Wolff J, et al. Further localization of a gene for paroxysmal dystonic choreoathetosis to a 5-cM region on chromosome 2q 34. Hum Genet 1998; 102: 93–7
Fink JK, Rainer S, Wilkowski J, et al. Paroxysmal dystonic choreoathetosis: tight linkage to chromosome 2q. Am J Hum Genet 1996; 59: 140–5
Fouad GT, Servidei S, Durcan S, et al. A gene for familial paroxysmal dyskinesia (FPD1) maps to chromosome 2q. Am J Hum Genet 1996; 59: 135–9
Auburger G, Ratzlaff T, Lunkes A, et al. A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S 197. Genomics 1996; 31: 90–4
Walker ES. Familial paroxysmal dystonic choreoathetosis: a neurologic disorder simulating psychiatric illness. Johns Hopkins Med J 1981; 148: 108–13
Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology 1967; 17: 680–90
Lance JW. Sporadic and familial varieties of tonic seizures. J Neurol Neurosurg Psychiatry 1963; 26: 51–9
Smith LA, Heersema PH. Periodic dystonia. Mayo Clin Proc 1941; 16: 842–6
Klein C, Brin MF, Kramer P, et al. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci U S A 1999; 96: 5173–6
Klein C, Breakefield X, Ozelius L. Genetics of primary dystonia. Semin Neurol 1999; 19: 271–80
Gasser T, Bereznai B, Muller B, et al. Linkage studies in alcohol-responsive myoclonic dystonia. Mov Disord 1996; 11: 363–70
Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q 31. Ann Neurol 1999; 46: 794–8
Brashear A, deLeon D, Bressman SB, et al. Rapid-onset dystonia-parkinsonism in a second family. Neurology 1997; 48(4): 1066–9
Ishikawa A, Miyatake T. A family with hereditary juvenile dystonia-parkinsonism. Mov Disord 1995; 10: 482–8
Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia-parkinsonism. Neurology 1993; 43: 2596–602
Kramer PL, Mineta M, Klein C, et al. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19ql3 [in process citation]. Ann Neurol 1999; 46: 176–82
Jun AS, Brown MD, Wallace DC. A mitochondrial DNA mutation at np 14459 of the ND6 gene associated with maternally inherited Leber’s hereditary optic neuropathy and dystonia. Proc Natl Acad Sci U S A 1994; 91: 6206–10
Novotny Jr EJ, Singh G, Wallace DC, et al. Leber’s disease and dystonia: a mitochondrial disease. Neurology 1986; 36: 1053–60
Risch N, de Leon D, Ozelius L, et al. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population [see comments]. Natl Genet 1995; 9: 152–9
Kramer PL, de Leon D, Ozelius L, et al. Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34 [see comments]. Ann Neurol 1990; 27: 114–20
Shashidharan P, Kramer BC, Walker RH, et al. Immunohisto-chemical localization and distribution of torsinA in normal human and rat brain. Brain Res 2000; 853: 197–206
Shashidharan P, Good PF, Hsu A, et al. Torsin A accumulation in Lewy bodies in sporadic Parkinson’s disease. Brain Res 2000; 877(2): 379–81
Augood SJ, Martin DM, Ozelius LJ, et al. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Ann Neurol 1999; 46: 761–9
Kustedjo K, Bracey MH, Cravatt BF. Torsin A and its torsion dystonia-associated mutant form are lumenal glycoproteins that exhibit distinct subcellular localizations. J Biol Chem 2000; 275(36): 27933–9
Hewett J, Gonzalez-Agosti C, Slater D, et al. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet 2000; 9: 1403–13
Oppenheim H. Uber eine eigenartige Krampfkrankheit des kindlichen und jungendichen Alters (dysbasia lordotica progressiva, dystonia musculorum deformans). Neuro Centrabl 1911; 30: 1090–107
Herz EM, Dystonia I. Historical review; analysis of dystonic symptoms and physiologic mechanisms involved. Arch Neurol Psychiatry 1944; 51: 305–55
Herz E. Dystonia III. Pathology and conclusions. Arch Neurol Psychiatry 1944; 52: 20–6
Herz E. Dystonia II. Clinical classification. Arch Neurol Psychiatry 1944; 51: 319–55
Cohen LG, Hallett M. Hand cramps: clinical features and electromyographic patterns in a focal dystonia. Neurology 1988; 38: 1005–12
Buchman AS, Cornelia CL, Leurgans S, et al. The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord 1998; 13: 490–6
Hallett M. Physiology of dystonia. Adv Neurol 1998; 78: 11–8
Kaji R, Rothwell JC, Katayama M, et al. Tonic vibration reflex and muscle afferent block in writer’s cramp. Ann Neurol 1995; 38: 155–62
Naumann M, Pirker W, Reiners K, et al. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord 1998; 13: 319–23
Perlmutter JS, Stambuk MK, Markham J, et al. Decreased [18F]spiperone binding in putamen in dystonia. Adv Neurol 1998; 78: 161–8
Sealfon SC, Olanow CW. Dopamine receptors: from structure to behavior. Trends Neurosci 2000; 23: S34–S40
Kanovsky P, Streitova H, Dufek J, et al. Lateralization of the P22/N30 component of somatosensory evoked potentials of the median nerve in patients with cervical dystonia. Mov Disord 1997; 12(4): 553–60
McEwen JE, Reilly PR. State legislative efforts to regulate use and potential misuse of genetic information [published erratum appears in Am J Hum Genet 1992 Dec; 51 (6): 1457]. Am J Hum Genet 1992; 51: 637–47
Mazzini L, Zaccala M, Balzarini C. Abnormalities of somatosensory evoked potentials in spasmodic torticollis. Mov Disord 1994; 9: 426–30
Naumann M, MagyarLehmann S, Reiners K, et al. Sensory tricks in cervical dystonia: perceptual dysbalance of parietal cortex modulates frontal motor programming. Ann Neurol 2000; 47(3): 322–8
Leis AA, Dimitrijevic MR, Delapasse JS, et al. Modification of cervical dystonia by selective sensory stimulation. J Neurol Sci 1992; 110: 79–89
Odergren T, Rimpilainen I, Borg J. Sternocleidomastoid muscle responses to transcranial magnetic stimulation in patients with cervical dystonia. Electromyogr Motor Control 1997; 105(1): 44–52
Amadio S, Panizza M, Pisano F, et al. Transcranial magnetic stimulation and silent period in spasmodic torticollis. Am J Phys Med Rehabil 2000; 79: 361–8
Samii A, Pal PK, Schulzer M, et al. Post-traumatic cervical dystonia: a distinct entity? Can J Neurol Sci 2000; 27(1): 55–9
Truong DD, Dubinsky R, Hermanowicz N, et al. Posttraumatic torticollis. Arch Neurol 1991; 48: 221–3
Tarsy D. Comparison of acute- and delayed-onset posttraumatic cervical dystonia. Mov Disord 1998: 13; 481–5
Schott GD. The relationship of peripheral trauma and pain to dystonia. J Neurol Neurosurg Psychiatry 1985; 48: 698–701
Duane DD, Clark M, Gottlob L. Elevated autoimmune antibody titers in cervical dystonia versus control. Neurology 1995; 45: A456
Kumar R, Maraganore DM, Ahlskog JE, et al. Treatment of putative immune-mediated and idiopathic cervical dystonia with intravenous methylprednisolone. Neurology 1997; 48: 732–5
Becker G, Berg D, Rausch WD, et al. Increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia. Ann Neurol 1999; 46(2): 260–3
Berg D, Weishaupt A, Francis MJ, et al. Changes of copper-transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult-onset dystonia. Ann Neurol 2000; 47(6): 827–30
Mezaki T, Matsumoto S, Hamada C, et al. Decreased serum ceruloplasmin and copper levels in cervical dystonia. Ann Neurol 2001; 49(1): 138–9
Weiner WJ, Lang AE. Idiopathic torsion dystonia. In: Weiner WJ, Lang AE, editors. Movement disorders: a comprehensive survey. New York: Futura, 1989: 347–418
Jankovic J, Fahn S. Dystonic syndromes. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore-Munich: Urban & Schwarzenberg, 1988: 283–314
Dauer WT, Burke RE, Greene P, et al. Current concepts on the clinical features, etiology and management of idiopathic cervical dystonia. Brain 1998; 121: 547–60
Scott BL. Evaluation and treatment of dystonia. South Med J 2000; 93: 746–51
Pal PK, Samii A, Schulzer M, et al. Head tremor in cervical dystonia. Can J Neurol Sci 2000; 27: 137–42
de Leon D, Moskowitz CB, Stewart C. Proposed guidelines for videotaping individuals with movement disorders. J Neurosci Nurs 1991; 23: 191–3
Klawans HL. Taking a Risk. Trials of an expert witness: tales of clinical neurology and the law. Boston: Little Brown, 1991: 93–4
Kraft IA. A psychiatric study of two patients with dystonia musculorum deformans. South Med J 1966; 59: 284–8
Tolosa ES. Clinical features of Meige’s disease (idiopathic or-ofacial dystonia). iA report of 17 cases. Arch Neurol 1981; 38: 147–51
Jahanshahi M, Marsden CD. Depression in torticollis: a controlled study. Psychol Med 1988; 18: 925–33
Jahanshahi M, Marsden CD. A longitudinal follow-up study of depression, disability, and body concept in torticollis. Behav Neurol 1990; 3: 233–46
Murry T, Cannito MP, Woodson GE. Spasmodic Dysphonia -emotional status and Botulinum toxin treatment. Arch Otolaryngol Head Neck Surg 1994; 120: 310–6
Lauterbach EC, Price ST, Spears TE, et al. Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in Thalamic Infarct associated with Myoclonus and Blepharospasm. Biol Psychiatry 1994; 35: 488–90
Jahanshahi M. Psychosocial factors and depression in torticollis. J Psychosom Res 1991; 35: 493–507
Wenzel T, Schnider P, Wimmer A, et al. Psychiatric comorbidity in patients with spasmodic torticollis. J Psychosom Res 1998; 44: 687–90
Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988; 3: 46–60
Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46: 1066–72
Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983; 225: 515–21
Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982; 11: 41–7
Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38: 391–4
Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358–62
Burke RE, Reches A, Traub MM, et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985; 17: 200–2
Burke RE, Fahn S, Mayeux R, et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981; 31: 1022–5
Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome [letter]. Mov Disord 1996; 11: 95
Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington’s disease. Clin Neuropharm 1992; 15: 63–8
Burbaud P, Guehl D, Lagueny A, et al. A pilot trial of clozapine in the treatment of cervical dystonia [letter]. J Neurol 1998; 245: 329–31
Thiel A, Dressier D, Kistel C, et al. Clozapine treatment of spasmodic torticollis. Neurology 1994; 44: 957–8
Karpati S, Desaknai S, Desaknai M, et al. Human herpesvirus type 8-positive facial angiosarcoma developing at the site of botulinum toxin injection for blepharospasm. Br J Dermatol 2000; 143: 660–1
Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 1973; 12: 924–7
Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17: 21–5
Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemi-facial spasm. Adv Neurol 1988; 50: 599–608
Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990; 40: 277–80
Cornelia CL, Buchman AS, Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42: 878–82
Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40: 1213–8
Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186–94
Brin MF. Interventional neurology: treatment of neurological conditions with local injection of botulinum toxin. Arch Neurobiol 1991; 54: 173–89
Jahanshahi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. J Neurol Neurosurg Psychiatry 1992; 55: 229–31
Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®. J Neurol Neurosurg Psychiatry 1998; 64(1): 13–7
Brans JW, Lindeboom R, Aramideh M, et al. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998; 50: 1461–3
Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group J Neurol 1999; 246: 265–74
Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport(R) and Botox(R) in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64(1):6–12
Dressler D, Rothwell JC. Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleido-mastoid muscle. Eur Neurol 2000; 43: 13–6
Brashear A, Bergan K, Wojcieszek J, et al. Patients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000; 15(1): 150–3
Astarloa R, Morales B, Sanchez V, et al. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin]. Arch Neurobiol 1991; 54 Suppl. 3: 44–51
Finsterer J, Fuchs I, Mamoli B. Automatic EMG-guided botulinum toxin treatment of spasticity. Clin Neuropharmacol 1997; 20(3): 195–203
Finsterer J, Fuchs I, Mamoli B. Quantitative electromyography-guided botulinum toxin treatment of cervical dystonia. Clin Neuropharmacol 1997; 20: 42–8
Brans JW, de Boer IP, Aramideh M, et al. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol 1995; 242: 529–34
Rollnik JD, Matzke M, Wohlfarth K, et al. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance — an open label study. Eur Neurol 2000; 43(1): 9–12
Brin MF, Blitzer A. Botulinum toxin — dangerous terminology errors. J R Soc Med 1993; 86: 494
Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A — Dysport and Botox — assuming a ratio of 4: 1. Mov Disord 1997; 12(6): 1013–8
Brashear A, Lew M F, Dykstra DD, et al. Safety & efficacy of Neurobloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53(7): 1439–46
Brin MF, Lew MF, Adler CH, et al. Safety & efficacy of Neurobloc (botulinum toxin type B) in type-A resistant cervical dystonia. Neurology 1999; 53(7): 1431–8
Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 1997; 20: S129–45
Brin MF. Treatment of dystonia. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. New York: Williams & Wilkins, 1998: 553–78
Brin MF, Blitzer A, Stewart C, et al. Disorders with excessive muscle contraction: candidates for treatment with intramuscular botulinum toxin (‘botox’). In: DasGupta BR, editor. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum, 1993: 559–76
Blitzer A, Binder WJ, Brin MF. Management of facial wrinkles with botulinum toxin injections. In: Krespi YP, editor. Office-based surgery of the head and neck. New York: Lippincott-Raven, 1998: 251–4
Blitzer A, Binder WJ, Boyd JB, et al. Management of facial lines and wrinkles. Philadelphia: Lippincott Williams & Wilkins, 1999
American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 1990; 40: 1332–6
National Institutes of Health Consensus Development Conference. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Statement, Nov 12–14, 1990. Arch Neurol 1991; 48: 1294–8
AAO-HNS. American Academy of Otolaryngology — Head and neck surgery policy statement: Botox for spasmodic dysphonia. AAO-HNS Bulletin 1990; 9: 8
Cornelia CL, Tanner CM, DeFoor-Hill L, et al. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology 1992; 42: 1307–10
Buchholz DW, Neumann S. The swallowing side effects of botulinum toxin type a injection in spasmodic dysphonia. Dysphagia 1997; 12: 59–60
Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B (BotB): a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49: 701–7
Allergan Pharmaceuticals. BOTOX® approved uses: cervical dystonia [online]. Available from URL: http//www.botox.com/index.jsp?hp&cervical [Accessed 2001 Sep 20]
Allergan Inc. BOTOX® package information. Irvine (CA), 2000
Paton JC, Lawrence AJ, Manson JI. Quantitation of Clostridium botulinum organisms and toxin in the feces of an infant with botulism. J Clin Microbiol 1982; 15: 1–4
Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45: 1743–6
Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresist-ant to botulinum toxin injections. Movement Disord 1998; 13(1): 150–4
Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta BR, editor. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press, 1993: 651–4
Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213–7
Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in Dystonic patients treated with Type-A Botulinum Toxin —frequency and significance. Neurology 1993; 43: 1715–8
Hatheway CH, Snyder JD, Seals JE, et al. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984; 150: 407–12
Dressier D, Dimberger G, Bhatia KP, et al. Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord 2000; 15: 973–6
Dezfulian M, Hatheway C, Yolken R, et al. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type A and type B toxins in stool samples of infants with botulism. J Clin Microbiol 1984; 20: 379–83
Dezfulian M, Bitar R, Bartlett J. Kinetics study of immunological response to Clostridium botulinum toxin. J Clin Microbiol 1987; 25: 1336–7
Tsui JK, Wong NLM, Wong E, et al. Production of circulating antibodies to botulinum-A toxin in patients receiving repeated injections for dystonia. Ann Neurol 1988; 24: 181
Doellgast GJ, Triscott MX, Beard GA, et al. Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J Clin Microbiol 1993; 31: 2402–9
Doellgast GJ, Beard GA, Bottoms JD, et al. Enzyme-linked immunosorbent assay and enzyme-linked coagulation assay for detection of Clostridium botulinum neurotoxin-A, neuro-toxin-B, and neurotoxin-E and solution-phase complexes with dual-label antibodies. J Clin Microbiol 1994; 32: 105–11
Siatkowski RM, Tyutyunikov A, Biglan AW, et al. Serum antibody production to botulinum-A toxin. Ophthalmology 1993; 100: 1861–6
Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998; 50: 1624–9
Greene PE, Fahn S. Use of botulinum toxin type-F injections to treat torticollis in patients with immunity to botulinum toxin type-A. Mov Disord 1993; 8: 479–83
Greene PE, Fahn S. Response to botulinum toxin f in seronegative botulinum toxin a — resistant patients. Mov Disord 1996; 11: 181–4
Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin [letter]. N Engl J Med 1992; 326: 349–50
Rhew K, Ludlow CL, Karp BI, et al. Clinical experience with botulinum toxin F. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 323–8
Sheean GL, Lees AJ. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. J Neurol Neurosurg Psychiatry 1995; 59: 601–7
Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998; 64: 577–80
Truong DD, Cullis PA, Obrien CF, et al. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Mov Disord 1997; 12(5): 772–5
Tsui JKC, Hayward M, Mak EKM, et al. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 1995; 45: 2109–10
Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of Neurobloc (botulinum toxin type-B) in type-A resistant cervical dystonia (CD) patients. Neurology 1999; 52 Suppl. 2: A293
Cullis PA, O’Brien CF, Truong DD, et al. Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. Adv Neurol 1998; 78: 227–30
Hatheway CL, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994; 93–107
Dodel RC, Kirchner A, Koehne-Volland R, et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 1997; 12: 695–706
Goschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies — therapeutic consequences. Exp Neurol 1997; 147(1): 96–102
Aoki R, Merlino G, Spanoyannis AF, et al. BOTOX (botulinum toxin type A) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical efficacy as the original but with reduced immunogenicity. Neurology 1999; 52 Suppl. 2: A521–A2
Racette BA, McGee-Minnich L, Perlmutter JS. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin Neuropharm 1999; 22: 337–9
Naumann M, Toyka KV, Mansouri TB, et al. Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiatry 1998; 65: 924–7
Duane DD, Monroe J, Morris RE. Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia. Mov Disord 2000; 15(2): 365–6
Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 1997; 48: 1440–2
Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986; 36: 545–7
Lange DJ, Warner C, Brin MF, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission [abstract]. Muscle Nerve 1985; 8: 624
Girlanda P, Vita G, Nicolosi C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992; 55: 844–5
Scott AB. Clostridial toxins as therapeutic agents. In: Simpson LL, editor. Botulinum neurotoxin and tetanus toxin. New York: Academic Press, 1989: 399–412
Moser E, Ligon KM, Singer C, et al. Botulinum toxin A (Botox) therapy during pregnancy [abstract]. Neurology 1997; 48: A399
Emerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994; 9: 367
Mezaki T, Kaji R, Kohara N, et al. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996; 46: 845–6
Erbguth F, Claus D, Engelhardt A, et al. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993; 56: 1235–6
Tuite PJ, Lang AE. Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996; 46: 846
Ruiz PJG, Bernardos VS. Intramuscular phenol injection for severe cervical dystonia. J Neurol 2000; 247(2): 146–7
Koman LA, Mooney JF III, Smith BP. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol 1996; 11 Suppl. 1: S23–8
Bodine-Fowler SC, Allsing S, Botte MJ. Time course of muscle atrophy and recovery following a phenol-induced nerve block. Muscle Nerve 1996; 19: 497–504
Poemnyi FA, Barsukova MD, Gutorova I. [Treatment of spastic torticollis with phenol-glycerin and alcohol-novocaine blockade]. Zh Nevropatol Psikhiatr Im S S Korsakova 1976; 76: 1326–30
Massey JM. Treatment of spasmodic torticollis with intramuscular phenol injection [letter]. J Neurol Neurosurg Psychiatry 1995; 58: 258–9
Bertrand C, Molina Negro P, Bouvier G, et al. Observations and analysis of results in 131 cases of spasmodic torticollis after selective denervation. Appl Neurophysiol 1987; 50: 319–23
Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg Neurol 1993; 40: 96–103
Cooper IS. Effects of thalamic lesions on torticollis. N Engl J Med 1964; 270: 967–72
Hassler R, Dieckmann G. Stereotactic treatment of different kinds of spasmodic torticollis. Confin Neurol 1970; 32: 135–43
Bertrand CM. The treatment of spasmodic torticollis with particular reference to thalamotomy. In: Mortley T, editor. Current controversies in neurosurgery. Philadelphia: WB Saunders, 1976: 455–9
Bertrand CM, Molina-Negro P, Martinez SN. Stereotactic targets for dystonias and dyskinesias: relationship to corticobulbar fibers and other adjoining structures. Adv Neurol 1979; 24: 395–9
Bertrand C, Molina-Negro P, Martinez SN. Combined stereo-tactic and peripheral surgical approach for spasmodic torticollis. Appl Neurophysiol 1978; 41: 122–33
Bertrand C, Molina NP, Martinez SN. Technical aspects of selective peripheral denervation for spasmodic torticollis. Appl Neurophysiol 1982; 45: 326–30
Bertrand CM. Stereotactic and peripheral surgery for the control ov movement disorders. In: Barbeau A, editor. Disorders of movements: current status of modern therapy. Lancaster: MTP Press, 1981: 191–208
Bertrand CM, Molina Negro P. Selective peripheral denervation in 111 cases of spasmodic torticollis: rationale and results. Adv Neurol 1988; 50: 637–43
Arce C, Russo L. Selective peripheral denervation: a surgical alternative in the treatment of spasmodic torticollis. Review of fifty five patients. Mov Disord 1992; 7: 128
Davis DH, Ahlskog JE, Litchy WJ, et al. Selective peripheral denervation for torticollis: preliminary results. Mayo Clin Proc 1991; 66: 365–71
Bertrand CM, Benabou R. Surgical treatment of spasmodic torticollis: selective peripheral denervation revisited. In: Germano I, editor. Neurosurgical treatment of movement disorders. Park Ridge: American Association of Neurological Surgeons, 1998: 239–54
Bertrand CM, Lenz FA. Surgical treatment of dystonias. In: Tsui JKC, Calne DB, editors. Handbook of dystonia, vol. 39. New York; Marcel Dekker, 1995: 329–46
Benabou R, Molina-Negro P, Bouvier G. Selection criteria for selective peripheral denervation for spasmodic torticollis. Can J Neurol Sci 1995; 22: S26
Krauss JK, Toups EG, Jankovic J, et al. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1997; 63(5): 642–8
Braun V, Richter HP. Selective peripheral denervation for the treatment of spasmodic torticollis. Neurosurgery 1994; 35: 58–62
Ford B, Louis ED, Greene P, et al. Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry 1998; 65: 472–8
McKenzie KG. Intrameningeal division of the spinal accessory roots of the upper cervical nerves for the treatment of spasmodic torticollis. Surg Gynecol Obstet 1924; 39: 5–10
Dandy WE. An operation for the treatment of spasmodic torticollis. Arch Surg 1930; 20: 1021–32
Adams CB. Spasmodic torticollis resulting from neurovascular compression. J Neurosurg 1987; 66: 635
Freckmann N, Hagenah R, Herrmann HD, et al. Bilateral microsurgical lysis of the spinal accessory nerve roots for treatment of spasmodic torticollis. Follow up of 33 cases. Acta Neurochir 1986; 83: 47–53
Adams CB. Vascular catastrophe following the Dandy McKenzie operation for spasmodic torticollis. J Neurol Neurosurg Psychiatry 1984; 47: 990–4
Friedman AH, Nashold BS, Sharp R, et al. Treatment of spasmodic torticollis with intradural selective rhizotomies. J Neurosurg 1993; 78: 46–53
Hamby WB, Schiffer S. Spasmodic torticollis; results after cervical rhizotomy in 50 cases. J Neurosurg 1969; 31: 323–6
Hamby WB, Schiffer S. Spasmodic torticollis; results after cervical rhizotomy in 80 cases. Clin Neurosurg 1970; 17: 28–37
Perot PL. Upper cervical ventral rhizotomy and selective section of spinal accessory rootlets for spasmodic torticollis. In: Wilson CB, editor. Neurosurgical procedures: personal approaches to classic operations. Baltimore: Williams & Wilkins, 1992: 163–8
Shima F, Fukui M, Kitamura K, et al. Diagnosis and surgical treatment of spasmodic torticollis of 1 lth nerve origin. Neurosurgery 1988; 22: 358–63
Jho HD, Jannetta PJ. Microvascular decompression for spasmodic torticollis. Acta Neurochir (Wien) 1995; 134: 21–6
Tasker RR. Outcome after stereotactic thalamotomy for dystonia and hemiballismus — comment. Neurosurgery 1995; 36: 507–8
Tasker RR, Doorly T, Yamashiro K. Thalamotomy in generalized dystonia. Adv Neurol 1988; 50: 615–32
Gros C, Frerebeau P, Perez-Dominguez E, et al. Long term results of stereotaxic surgery for infantile dystonia and dyskinesia. Neurochirurgia Stuttg 1976; 19: 171–8
Caracalos A. Results of 103 cryosurgical procedures in involuntary movement disorders. Confin Neurol 1972; 34: 74–83
Cooper IM, Bravo GM. Alleviation of dystonia musculorum deformans and other involuntary movement disorders of childhood by chemopallidectomy and chemopallido-thalamectomy. Clin Neurosurg 1958; 5: 127–49
Vitek JL, Zhang J, Evatt M, et al. GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Adv Neurol 1998; 78: 211–9
Iacono RP, Kuniyoshi SM, Lonser RR, et al. Simultaneous bilateral pallidoansotomy for idiopathic dystonia musculorum deformans. Pediatr Neurol 1996; 14: 145–8
Shima F, Sakata S, Sun S-J, et al. The role of the descending pallido-reticular pathway in movement disorders. In: Segawa M, Nomura Y, editors. Age-related dopamine-dependent disorders, vol. 14. New York: Karger, 1995: 197–207
Islekel S, Zileli M, Zileli B. Unilateral pallidal stimulation in cervical dystonia. Stereotact Funct Neurosurg 1999; 72: 248–52
Krauss JK, Pohle T, Weber S, et al. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia [letter]. Lancet 1999; 354: 837–8
Acknowledgements
The Bachmann-Strauss Dystonia and Parkinson’s Foundation, and FD-R-001452 grant. Dr Velickovic and Dr Benabou have nothing to disclose. Dr Brim is Vice President Development BOTOX®/Neurology Allergan Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Velickovic, M., Benabou, R. & Brin, M.F. Cervical Dystonia. Drugs 61, 1921–1943 (2001). https://doi.org/10.2165/00003495-200161130-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200161130-00004